secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001628280-23-034587
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx secures up to $100M additional debt; $50M committed Term C loan drawable by Mar 2024
--------------------------------------------------------------------------------

- Third Amendment adds $22.5M Term B loan (existing commitment) and $50M committed Term C loan drawable by March 15, 2024.
- Uncommitted $50M Term D loan available through Dec 2026, subject to SLR investment committee approval.
- Interest rates: Term A/B at SOFR + 7.95% (floor 1.00%); Term C/D at SOFR + 4.25% (floor 4.70%); maturity extended to March 1, 2027.
- Interest-only period for existing tranches extended to Dec 31, 2026 upon drawing Term B loan; prepayment premiums: 3%/2%/1% declining.
- Term B loan draw conditioned on FDA approval of tenapanor for hyperphosphatemia by Nov 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023034587/0001628280-23-034587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023034587/ardx-20231017.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-034587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer